




Applied Genetic Technologies Corporation
Investor Relations Department
14193 NW 119th Terrace
Suite 10
Alachua, FL 32615
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AGTC

Last Trade:	3.80
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	-0.05  (1.299%)
Day Range	3.70 - 3.90
52-Week Range	3.50 - 10.85
Volume	117,744

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates focus on inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.

AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLR5), X-linked r... [\(more\)](#))

Stock Performance



Press Releases [\[View all \]](#)

- Oct 6, 2017*
[AGTC and the Medical College of Wisconsin Announce Publication of Natural History Data Examining Foveal Cone Structure in Patients with CNGB3-associated Achromatopsia](#)
- Sep 29, 2017*
[AGTC to Present at Upcoming Gene Therapy Conferences](#)
- Sep 20, 2017*
[AGTC to Present at Upcoming Conferences](#)
- Sep 13, 2017*
[AGTC Announces Financial Results and Business Update for the Quarter and Fiscal Year Ended June 30, 2017](#)
- Sep 5, 2017*
[AGTC Appoints Matthew Feinsod, M.D. as Interim Chief Medical Officer](#)

Financials [\[View all \]](#)

- Sep 13, 2017*
[Annual Report \(10-K\)](#)
- Jan 13, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2017*
[Quarterly Report \(10-Q\)](#)
- Feb 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*
[Quarterly Report \(10-Q\)](#)